# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $7 t...
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate.
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical compan...
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's select...
Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight.
Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Neutral and maintains $3.5 price target.
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 t...